Anti-tumor and anti-metastatic effects of gelatin-doxorubicin and PEGylated gelatin-doxorubicin nanoparticles in SCC7 bearing mice
- Authors
- Lee, Gee Young; Park, Kyeongsoon; Nam, Jong Hee; Kim, Sang Yoon; Byun, Youngro
- Issue Date
- Dec-2006
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- PEGylated gelatin; doxorubicin; nanoparticle; anti-tumor; anti-metastasis
- Citation
- JOURNAL OF DRUG TARGETING, v.14, no.10, pp 707 - 716
- Pages
- 10
- Journal Title
- JOURNAL OF DRUG TARGETING
- Volume
- 14
- Number
- 10
- Start Page
- 707
- End Page
- 716
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/51454
- DOI
- 10.1080/10611860600935701
- ISSN
- 1061-186X
1029-2330
- Abstract
- The goal of this study was to develop a systemically non-toxic and stable circulation based passive targeting system for efficient anticancer treatment. Gelatin-doxorubicin (GD) and PEGylated gelatin-doxorubicin (PGD) nanoparticles were designed and their feasibilities as an anti-cancer drug were evaluated. The sizes of GD and PGD nanoparticles were about 135 and 250nm, respectively, and they retained their structures for 2 days in PBS. Both GD and PGD had much lower cytotoxicity in vitro and in vivo than doxorubicin (DOX) at equivalent concentrations. However, PGD significantly inhibited tumor growth compared to the control and DOX treated group, and GD moderately suppressed tumor growth compared with the control but the suppressing effect of GD did not exceed that of DOX. And GD and PGD both remarkably suppressed pulmonary metastasis. We conclude that PGD is a potential cancer therapeutic, due to its excellent anti-tumor and anti-metastatic effects and low systemic toxicity.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Biotechnology & Natural Resource > Department of Systems Biotechnology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.